Long-Term HIV Treatment Research Data Published in Leading Clinical Journal
May 30, 2023 — Five-year cumulative data from two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) has been published in eClinicalMedicine, a Lancet journal publication. The Week 240 results further reinforce Biktarvy’s role as a guidelines recommended treatment option for a broad range of people with HIV and demonstrated the sustained efficacy and durable viral suppression of the single-tablet regimen. The data support the long-term use of Biktarvy, with no significant changes to metabolic, bone, and renal health markers through five years.
These five-year results demonstrating Biktarvy’s sustained efficacy and safety profile, durable viral suppression, and high barrier to resistance are clinically important because most studies of HIV therapies generally follow participants through to standard primary and secondary endpoints, i.e., 48 and 96 weeks, respectively.
Through five years of analysis, zero cases of treatment failure due to emergent resistance were detected among the final resistance analysis population of both studies. A medication with a high barrier to resistance is a key consideration when initiating treatment of HIV in adults with no prior antiretroviral therapy history.
Please click here to view the full Prescribing Information for BIKTARVY, including Boxed Warning.
Please advise if you are interested in speaking with a study investigator or a Gilead spokesperson for more details on the HIV treatment research data published in eClinicalMedicine.
BIKTARVY, Gilead, and the Gilead Logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
333 Lakeside Drive, Foster City, CA 94404
©2023 Gilead Sciences, Inc. All rights reserved.
Contact:
Brian Plummer,
Senior Director, Global Public Affairs – HIV
brian.plummer@gilead.com
Source: Gilead Sciences, Inc.
"Reproduced with permission - Gilead Sciences, Inc."
Gilead Sciences, Inc.
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
